ALLMedicine™ B-cell Lymphoma Center

Jan 16th, 2022 - This was an open-label, phase 1b study assessing the safety, tolerability, preliminary efficacy and pharmacokinetics of the combination of atezolizumab and obinutuzumab in patients with relapsed/refractory follicular lymphoma (FL) or diffuse large...

Jan 15th, 2022 - Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-cell lymphoma (DLBCL) patients from China, an endemic area of HBV infection, have chronic HBV infec...

Jan 15th, 2022 - No head-to-head trials have compared the efficacy of tisagenlecleucel versus historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overa...

Jan 14th, 2022 - This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in individuals with circulating ...

Jan 14th, 2022 - The sole distinguishing feature of follicular lymphoma grade 3B and diffuse large B-cell lymphoma is the growth pattern assessed by histopathology analysis. Diffuse growth defines diffuse large B-cell lymphoma but the clinical relevance of this fi...

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

Jan 5th, 2019 - The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.|2019|Cwynarski K,Marzolini MAV,Barrington SF,Follows G,Illidge T,|adverse effects,therapeutic use,chemically induced,diagnostic imaging,t...

Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,

Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...

Jan 14th, 2022 - Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

Jan 14th, 2022 - This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in individuals with circulating ...

Jan 14th, 2022 - In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maxim...

Jan 13th, 2022 - The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL...

Jan 12th, 2022 - BACKGROUND: We have constructed a retroviral vector that encodes an anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) that recognizes the CD19 antigen. This chimeric receptor also contains the signaling domains of cluster o...

Jan 13th, 2022 - OncLive® Rapid Readout from Primary Analysis of ZUMA‑7: a Phase 3 Randomized Trial of Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma Segment Description: Frederick L. Locke, MD...

Jan 12th, 2022 - The FDA has granted a regenerative medicine advanced therapy (RMAT) designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).1 A n...

Jan 11th, 2022 - Polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP; pola-R-CHP) showcased several benefits over R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone...

Jan 6th, 2022 - Brad Kahl, MD, shares results from non-Hodgkin lymphoma clinical trials that were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Dr Kahl looks first at a frontline study examining a new combination therapy.

Jan 5th, 2022 - Treatment options for patients with Waldeström macroglobulinemia (WM) are often derived from those developed for patients with multiple myeloma and other low-grade lymphomas. Patients with WM are relatively rare. Their disease is defined as lympho...